Back To The Drawing Board For Double Bond's Temodex Mission
A failed deal has left Double Bond Pharmaceuticals again on the search for a partner in order to take its lead products forward. CEO Igor Lokot shares next steps and partnering plans.
You may also be interested in...
Daiichi teams with Glycotope on an antibody-drug conjugate for cancer, while Alector will partner with AbbVie to research antibody targets for Alzheimer’s disease.
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.